Calidi Biotherapeutics (CLDI) AI Stock Analysis

• Market Cap: $8.03M
• Dividend Yield: N/A
• Average Volume (3M): 164.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 87.42%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.21
• Shares Outstanding: 7,167,721
• 10 Day Avg. Volume: 193,319
• 30 Day Avg. Volume: 164,153
• PEG Ratio: <0.01
• Price to Book (P/B): 5.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.47
• Enterprise Value/Market Cap: 0.02
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.12
• Enterprise Value/Ebitda: -0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-10.71% Downside)

The score is held down primarily by continued lack of revenue, sizable losses, and heavy cash burn, which create ongoing financing/dilution risk. Technicals add further pressure with a clear downtrend and weak momentum. Offsetting factors include improved leverage/positive equity and constructive corporate updates (financing and development progress), but they are not enough to outweigh the core financial and trend risks.

Positive Factors

Scientific Advisory Board Formation

The formation of a Scientific Advisory Board enhances Calidi's research capabilities and strategic direction, potentially accelerating the development of its RedTail platform and strengthening its competitive position in the biotechnology industry.

Debt Reduction

Significant debt reduction improves financial stability and reduces interest expenses, enhancing Calidi's ability to allocate resources towards R&D and strategic initiatives, which is crucial for long-term growth in the biotech sector.

New Data on CLD-401

The promising new data on CLD-401 suggests potential efficacy in cancer treatment, which could lead to successful clinical trials and eventual commercialization, strengthening Calidi's market position in oncology therapeutics.

Negative Factors

High Cash Burn

High cash burn rate indicates reliance on external funding, which poses a risk to financial sustainability. This can lead to dilution or increased debt, impacting long-term viability unless revenue generation improves.

Lack of Revenue

The absence of revenue underscores the challenge of achieving profitability. Without a revenue stream, Calidi remains dependent on external funding, which could hinder its ability to invest in growth and innovation.

Ongoing Losses

Persistent losses highlight operational inefficiencies and the need for cost management. This financial strain could limit Calidi's ability to invest in R&D and strategic initiatives, affecting long-term competitiveness.

Calidi Biotherapeutics Business Overview & Revenue Model

Company Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

How the Company Makes Money

Calidi Biotherapeutics generates revenue through the development and commercialization of its proprietary oncolytic virus-based cancer therapies. The company's revenue streams are primarily derived from partnerships with pharmaceutical companies, licensing agreements, and potential sales of its therapeutic products upon regulatory approval. Calidi collaborates with academic institutions and industry partners to advance its research and clinical trials, which may include milestone payments and royalties from successful commercialization efforts. Additionally, the company may seek funding through grants, equity financing, or strategic alliances to support its research and development activities.

Calidi Biotherapeutics Financial Statement Overview

Summary

Calidi Biotherapeutics exhibits common financial traits of early-stage biotech firms, with no revenue and significant operational losses. Despite some balance sheet improvements, the company continues to face liquidity challenges and relies heavily on external funding.

Income Statement

Calidi Biotherapeutics has faced consistent revenue challenges with no recorded revenue in recent years, leading to negative net income and EBIT margins. The lack of revenue growth and persistent losses highlight significant profitability concerns, typical in early-stage biotech companies focused on R&D.

Balance Sheet

The company's balance sheet reveals high leverage with a debt-to-equity ratio that has improved to a positive equity position in 2024 from negative equity in previous years. The improvement in stockholders' equity suggests some stabilization, but overall financial health remains fragile with a significant debt load.

Cash Flow

The cash flow analysis indicates operational struggles with negative operating and free cash flows. The reliance on external financing to cover operational expenses underscores liquidity pressures. Although there has been some improvement in free cash flow from 2023 to 2024, sustainability concerns persist.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	45.00K	449.00K	0.00
Gross Profit	-1.62M	0.00	-1.26M	-229.00K	355.00K	0.00
EBITDA	-18.17M	-19.73M	-24.20M	-25.00M	-9.45M	-6.67M
Net Income	-19.95M	-22.14M	-29.22M	-25.43M	-10.93M	-7.94M
Balance Sheet
Total Assets	14.03M	14.18M	10.02M	2.60M	3.39M	1.85M
Cash, Cash Equivalents and Short-Term Investments	10.38M	9.59M	2.05M	372.00K	2.14M	420.00K
Total Debt	3.11M	7.04M	7.24M	5.99M	5.18M	11.72M
Total Liabilities	6.83M	12.21M	18.25M	53.04M	26.00M	24.33M
Stockholders Equity	6.92M	1.53M	-8.23M	-50.44M	-22.61M	-22.48M
Cash Flow
Free Cash Flow	-21.77M	-19.71M	-27.57M	-13.64M	-7.98M	-5.18M
Operating Cash Flow	-21.67M	-19.69M	-26.98M	-13.21M	-7.77M	-4.83M
Investing Cash Flow	-96.00K	-16.00K	-478.00K	-494.00K	-215.00K	-388.00K
Financing Cash Flow	30.23M	27.36M	29.04M	12.09M	9.81M	4.70M

Calidi Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.36, and below the 200-day MA of 3.39, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 28.24 is Positive, neither overbought nor oversold. The STOCH value of 23.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.

Calidi Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JAGX	45 Neutral	$2.86M	-0.02	-370.95%	―	12.45%	-544.23%
CLDI	44 Neutral	$8.03M	-0.12	―	―	―	87.42%
GLMD	44 Neutral	$4.51M	-0.22	-46.34%	―	―	70.71%
ADIL	41 Neutral	$6.20M	-0.25	-155.01%	―	―	78.52%

Calidi Biotherapeutics Corporate Events

Calidi Biotherapeutics Raises $6.9 Million in Offering

Calidi Biotherapeutics reported its third quarter 2025 financial results and operational highlights, showcasing advancements in its RedTail platform and CLD-401 compound. The company presented promising preclinical data at the SITC meeting and established a Scientific Advisory Board to support its development efforts. Additionally, Calidi raised $6.9 million through a public offering, strengthening its financial position. Despite a net loss of $5.2 million for the quarter, the company continues to expand its platform capabilities and explore new therapeutic areas, aiming to enhance its industry positioning in virotherapy and genetic medicine delivery.

The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Calidi Biotherapeutics Unveils New Data on CLD-401

On November 7, 2025, Calidi Biotherapeutics presented new data on its first therapeutic candidate, CLD-401, from the RedTail platform at the Society of Immunotherapy for Cancer Annual Meeting. This presentation, which included a webinar and a poster, highlights the company’s ongoing efforts to advance cancer treatment and potentially strengthen its position in the biotechnology sector.

The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Calidi Biotherapeutics Sells Majority Stake in Nova Cell

On October 27, 2025, Calidi Biotherapeutics entered into agreements with its former subsidiary, Nova Cell, Inc., to sell 22,500,000 shares of Nova Cell common stock, representing 75% of equity interest, for $6 million. This transaction, which includes a combination of debt cancellation and deferred consideration, results in Nova Cell no longer being a subsidiary of Calidi Biotherapeutics. The company anticipates annual savings of $0.5 million in general and administrative expenses following the sale. Additionally, the Material Purchase Agreement amends previous intellectual property arrangements, allowing Nova Cell to assume certain liabilities while Calidi retains stocks of specific cell lines for its use.

The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Calidi Biotherapeutics Forms New Advisory Board

On October 22, 2025, Calidi Biotherapeutics announced the formation of a new scientific advisory board aimed at advancing its RedTail platform and progressing CLD-401 into clinical trials. This strategic move is expected to enhance the company’s operational capabilities and strengthen its position in the biotechnology industry.

The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.